Broadfin Capital LLC continued to hold its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,200,000 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Broadfin Capital LLC owned 9.90% of Catalyst Pharmaceuticals worth $8,610,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Royal Bank of Canada acquired a new stake in Catalyst Pharmaceuticals during the second quarter worth $117,000. Berson & Corrado Investment Advisors LLC raised its stake in Catalyst Pharmaceuticals by 76.1% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 181,900 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 78,600 shares during the last quarter. Finally, Baker BROS. Advisors LP acquired a new stake in Catalyst Pharmaceuticals during the third quarter worth $5,561,000. 28.13% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) traded down 0.88% during midday trading on Thursday, reaching $1.12. 279,508 shares of the company’s stock were exchanged. The stock’s market cap is $92.81 million. Catalyst Pharmaceuticals, Inc. has a 12 month low of $0.51 and a 12 month high of $1.58. The firm has a 50 day moving average of $1.15 and a 200-day moving average of $1.09.

“Broadfin Capital LLC Continues to Hold Stake in Catalyst Pharmaceuticals, Inc. (CPRX)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at

Separately, Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 5th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $3.38.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

5 Day Chart for NASDAQ:CPRX

Want to see what other hedge funds are holding CPRX? Visit to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX).

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.